BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
Taking everything into account, BRM scores 5 out of 10 in our fundamental rating. BRM was compared to 50 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM is valued quite cheap, while showing a decent growth score. This is a good combination! Finally BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -9.66%, BRM is not doing good in the industry: 68.00% of the companies in the same industry are doing better.
With a Return On Equity value of -54.78%, BRM is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
With a decent Return On Invested Capital value of 11.77%, BRM is doing good in the industry, outperforming 66.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 14.89%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(11.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -54.78% | ||
| ROIC | 11.77% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM has a Operating Margin of 23.90%. This is in the better half of the industry: BRM outperforms 74.00% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
BRM's Gross Margin of 75.26% is fine compared to the rest of the industry. BRM outperforms 68.00% of its industry peers.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.9% | ||
| PM (TTM) | N/A | ||
| GM | 75.26% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BRM is creating some value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
The number of shares outstanding for BRM has been reduced compared to 5 years ago.
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
BRM has an Altman-Z score of 2.01. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.01, BRM perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.56, which is a good value as it means it would take BRM, 3.56 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.56, BRM is doing good in the industry, outperforming 66.00% of the companies in the same industry.
BRM has a Debt/Equity ratio of 2.93. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BRM (2.93) is worse than 78.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.93 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.01 |
ROIC/WACC1.37
WACC8.62%
2.3 Liquidity
A Current Ratio of 1.25 indicates that BRM should not have too much problems paying its short term obligations.
BRM has a Current ratio of 1.25. This is comparable to the rest of the industry: BRM outperforms 42.00% of its industry peers.
A Quick Ratio of 1.15 indicates that BRM should not have too much problems paying its short term obligations.
The Quick ratio of BRM (1.15) is better than 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
BRM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -84.80%.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 7.32%.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)-84.8%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-1.76%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%7.54%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 38.96% on average per year.
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.38% yearly.
EPS Next Y498.29%
EPS Next 2Y132.62%
EPS Next 3Y75.28%
EPS Next 5Y38.96%
Revenue Next Year-4.5%
Revenue Next 2Y-5.28%
Revenue Next 3Y-3.65%
Revenue Next 5Y-4.38%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 41.50, the valuation of BRM can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as BRM.
The average S&P500 Price/Earnings ratio is at 28.79. BRM is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 6.92 indicates a rather cheap valuation of BRM.
Based on the Price/Forward Earnings ratio, BRM is valued cheaper than 94.00% of the companies in the same industry.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.5 | ||
| Fwd PE | 6.92 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 82.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 90.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.89 | ||
| EV/EBITDA | 6.46 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM's earnings are expected to grow with 75.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y132.62%
EPS Next 3Y75.28%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.09%, which is a nice return.
The stock price of BRM dropped by -26.73% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
BRM's Dividend Yield is rather good when compared to the industry average which is at 3.15. BRM pays more dividend than 90.00% of the companies in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.09% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
The earnings of BRM are negative and hence is the payout ratio. BRM will probably not be able to sustain this dividend level.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP-54.35%
EPS Next 2Y132.62%
EPS Next 3Y75.28%
FRA:BRM (4/25/2025, 7:00:00 PM)
41.5
-1.1 (-2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.77%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap84.44B
Analysts68.39
Price Target50.45 (21.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.09% |
Yearly Dividend2.13
Dividend Growth(5Y)11.67%
DP-54.35%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.53%
Min EPS beat(2)13.54%
Max EPS beat(2)19.51%
EPS beat(4)4
Avg EPS beat(4)15.2%
Min EPS beat(4)1.78%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)9.24%
EPS beat(12)11
Avg EPS beat(12)8.32%
EPS beat(16)14
Avg EPS beat(16)6.25%
Revenue beat(2)2
Avg Revenue beat(2)5.02%
Min Revenue beat(2)4.41%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.3%
Min Revenue beat(4)2.53%
Max Revenue beat(4)5.63%
Revenue beat(8)5
Avg Revenue beat(8)1.2%
Revenue beat(12)8
Avg Revenue beat(12)1.22%
Revenue beat(16)9
Avg Revenue beat(16)0.88%
PT rev (1m)-1.78%
PT rev (3m)-1.15%
EPS NQ rev (1m)-0.65%
EPS NQ rev (3m)-17.49%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-4.18%
Revenue NQ rev (1m)0.25%
Revenue NQ rev (3m)-7.22%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-4.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.5 | ||
| Fwd PE | 6.92 | ||
| P/S | 1.99 | ||
| P/FCF | 6.89 | ||
| P/OCF | 6.32 | ||
| P/B | 5.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.46 |
EPS(TTM)1
EY2.41%
EPS(NY)6
Fwd EY14.45%
FCF(TTM)6.02
FCFY14.51%
OCF(TTM)6.56
OCFY15.81%
SpS20.87
BVpS7.06
TBVpS-12.39
PEG (NY)0.08
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -54.78% | ||
| ROCE | 16.77% | ||
| ROIC | 11.77% | ||
| ROICexc | 13.97% | ||
| ROICexgc | 61.75% | ||
| OM | 23.9% | ||
| PM (TTM) | N/A | ||
| GM | 75.26% | ||
| FCFM | 28.87% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.98%
ROICexgc(3y)70.34%
ROICexgc(5y)71.31%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score3
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.93 | ||
| Debt/FCF | 3.56 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 13% | ||
| Cap/Sales | 2.58% | ||
| Interest Coverage | 6.41 | ||
| Cash Conversion | 71.84% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 2.01 |
F-Score3
WACC8.62%
ROIC/WACC1.37
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-84.8%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-1.76%
EPS Next Y498.29%
EPS Next 2Y132.62%
EPS Next 3Y75.28%
EPS Next 5Y38.96%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%7.54%
Revenue Next Year-4.5%
Revenue Next 2Y-5.28%
Revenue Next 3Y-3.65%
Revenue Next 5Y-4.38%
EBIT growth 1Y6.4%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year280.12%
EBIT Next 3Y50.48%
EBIT Next 5Y27.12%
FCF growth 1Y10.2%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y9.6%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%